FibroGen Inc. (NASDAQ: FGEN), a biopharmaceutical organization, experienced an alarming 30% decline in share prices over 21 sessions since following NASDAQ’s downward trend. FibroGen last closed 92.21% beneath its 52-week high point.
Product Portfolio and Earnings Overview
FibroGen offers an impressive product portfolio highlighted by Pamrevlumab and Roxadustat, which are progressing through Phase III clinical trials. However, despite a dramatic drop in its share price, FibroGen reported a trailing twelve month earnings per share (EPS) figure of 2.84.
Return on Equity and Operational Profitability
FibroGen showed an alarmingly negative return on equity of -411.93% over its trailing twelve month period – indicating it has lost money relative to shareholders’ investments in it. Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA), which serves as an indication of operational profitability for companies, for this company totaled -$19.6 million.
Revenue Growth
Additionally, the company reported an alarming decline in revenue growth with an unexpected YoY quarterly revenue decrease of 40.6%. Investors should take note that decreasing revenues often indicate reduced business activity or failed expansion strategies.
Market Forces and Investor Perspectives
FibroGen’s share prices may have taken a tumble due to recent losses and declining revenues, but market forces could also be at play here. Investors likely keep an eye on how FibroGen progresses with clinical trials for its lead product candidates which could provide an upward boost if successful.
More news about FibroGen (FGEN).
